Skip to main content
×
×
Home

Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association

  • Siddharth Sarkar (a1) and Nitin Gupta (a2)
Summary

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal adverse event associated with the use of antipsychotics. Although atypical antipsychotics were initially considered to carry no risk of NMS, reports have accumulated over time implicating them in NMS causation. Almost all atypical antipsychotics have been reported to be associated with NMS. The clinical profile of NMS caused by certain atypical antipsychotics such as clozapine has been reported to be considerably different from the NMS produced by typical antipsychotics, with diaphoresis encountered more commonly, and rigidity and tremor encountered less frequently. This article briefly discusses the evidence relating to the occurrence, presentation and management of NMS induced by atypical antipsychotics.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association
      Available formats
      ×
Copyright
This is an open-access article published by the Royal College of Psychiatrists and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Correspondence to Nitin Gupta (nitingupta659@yahoo.co.in)
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Trollor, JN, Chen, X, Chitty, K, Sachdev, PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 2012; 201: 52–6.
2 Langan, J, Martin, D, Shajahan, P, Smith, DJ. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry 2012; 12: 214.
3 Strawn, JR, Keck, PE, Caroff, SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870–6.
4 Gurrera, RJ, Caroff, SN, Cohen, A, Carroll, BT, DeRoos, F, Francis, A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011; 72: 1222–8.
5 Adityanjee, , Sajatovic, M, Munshi, KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005; 28: 197204.
6 Modi, S, Dharaiya, D, Schultz, L, Varelas, P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocritical Care 2016; 24: 97103.
7 Nakamura, M, Yasunaga, H, Miyata, H, Shimada, T, Horiguchi, H, Matsuda, S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry 2012; 73: 427–30.
8 Tarsy, D, Baldessarini, RJ, Tarazi, FL. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16: 2345.
9 Belvederi Murri, M, Guaglianone, A, Bugliani, M, Calcagno, P, Respino, M, Serafini, G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs RD 2015; 15: 4562.
10 Trollor, JN, Chen, X, Sachdev, PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23: 477–92.
11 Pope, HG, Cole, JO, Choras, PT, Fulwiler, CE. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493–5.
12 Patel, NC, Crismon, ML, Hoagwood, K, Johnsrud, MT, Rascati, KL, Wilson, JP, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44: 548–56.
13 Verdoux, H, Tournier, M, Bégaud, B. Antipsychotic prescribing trends: a review of pharmacoepidemiological studies. Acta Psychiatr Scand 2010;121: 410.
14 Buckley, PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001; 50: 912–24.
15 Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6.
16 Owens, DC. How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Adv Psychiatr Treat 2008; 14: 1728.
17 Ananth, J, Parameswaran, S, Gunatilake, S, Burgoyne, K, Sidhom, T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464–70.
18 Jann, MW, Grimsley, SR, Gray, EC, Chang, WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24: 161–76.
19 Amore, M, Zazzeri, N, Berardi, D. Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology 1997; 35: 197–9.
20 Karagianis, JL, Phillips, LC, Hogan, KP, LeDrew, KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999; 33: 623–30.
21 Licup, N, Baumrucker, SJ. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 2010; 27: 432–4.
22 Musshoff, F, Doberentz, E, Madea, B. Lethal neuroleptic malignant syndrome due to amisulpride. Forensic Sci Med Pathol 2013; 9: 218–20.
23 Tsai, JH, Yang, P, Yen, JY, Chen, CC, Yang, MJ. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy 2005; 25: 1156–9.
24 Horacek, J, Bubenikova-Valesova, V, Kopecek, M, Palenicek, T, Dockery, C, Mohr, P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20: 389409.
25 Detweiler, MB, Sullivan, K, Sharma, TR, Kim, KY, Detweiler, JG. Case reports of neuroleptic malignant syndrome in context of quetiapine use. Psychiatr Q 2013; 84: 523–41.
26 Chen, Y-T, Su, K-P, Chang, JP-C. Early detection and management of atypical neuroleptic malignant syndrome secondary to aripiprazole. Schizophr Res 2011; 132: 97–8.
27 Tseng, PT, Chang, YC, Chang, CH, Wang, HY, Cheng, YS, Wu, CK, et al. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. Int J Psychiatry Med 2015; 49: 3543.
28 Leibold, J, Patel, V, Hasan, RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Therapeut 2004; 26: 1105–8.
29 Ozen, ME, Yumru, M, Savas, HA, Cansel, N, Herken, H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry 2007; 8: 42–4.
30 Mantas, C, Kalabokis, G, Goulia, P, Tourlakopoulos, A, Hyphantis, T, Mavreas, V. Possible neuroleptic malignant syndrome during paliperidone administration: a case report. J Clin Psychopharmacol 2010; 30: 8991.
31 Teng, PR, Lane, HY. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone. J Neuropsychiatry Clin Neurosci 2011; 23: E16.
32 Hsu, W-C, Lin, S-T, Chen, C-C, Tsang, H-Y, Huang, M-F. A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine. J Clin Psychopharmacology 2011; 31: 667–9.
33 Guanci, N, Aggarwal, R, Schleifer, S. Atypical neuroleptic malignant syndrome associated with iloperidone administration. Psychosomatics 2012; 53: 603–5.
34 Ohoyama, K, Tanii, H, Motomura, E, Konishi, Y, Nakagawa, M, Matsumoto, T, et al. Neuroleptic malignant syndrome induced by blonanserin. J Neuropsychiatry Clin Neurosci 2011; 23: E13.
35 Patel, MK, Brunetti, L. Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient. Am J Health Syst Pharm 2010; 67: 1254–9.
36 Borovicka, MC, Bond, LC, Gaughan, KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother 2006; 40: 139–42.
37 Su, YP, Chang, CK, Hayes, RD, Harrison, S, Lee, W, Broadbent, M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 2014; 130: 5260.
38 Picard, LS, Lindsay, S, Strawn, JR, Kaneria, RM, Patel, NC, Keck, PE Jr. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28: 530–5.
39 Caroff, SN, Mann, SC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000; 30: 314–21.
40 Levenson, JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137–45.
41 Addonizio, G, Susman, VL, Roth, SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986; 143: 1587–90.
42 Odagaki, Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Cure Drug Saf 2009; 4: 8493.
43 Susman, VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001; 72: 325–36.
44 Frucht, SJ. Treatment of movement disorder emergencies. Neurotherapeutics 2014; 11: 208–12.
45 Anbalagan, E, Ithman, M, Lauriello, J. Rechallenging clozapine after neuroleptic malignant syndrome. Psychiatr Q 2014; 85: 345–8.
46 Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180–6.
47 Mendhekar, DN, Jiloha, RC, Mehndiratta, MM, War, L. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. In J Psychiatry 2002; 44: 387–90.
48 Ross, C. Successful clozapine rechallenge following clozapine-induced neuroleptic malignant syndrome. Ment Health Clin 2015; 5: 8890.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 2056-4694
  • EISSN: 2056-4708
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 47 *
Loading metrics...

Abstract views

Total abstract views: 96 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 23rd June 2018. This data will be updated every 24 hours.

Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association

  • Siddharth Sarkar (a1) and Nitin Gupta (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *